BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16753589)

  • 21. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.
    Espinosa I; Catasus L; Canet B; D'Angelo E; Muñoz J; Prat J
    Mod Pathol; 2011 Jun; 24(6):846-54. PubMed ID: 21317880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
    Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays.
    O'Toole SA; Dunn E; Sheppard BL; Klocker H; Bektic J; Smyth P; Martin C; Sheils O; O'Leary JJ
    Int J Gynecol Cancer; 2006; 16(2):834-42. PubMed ID: 16681770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.
    Têtu B; Popa I; Bairati I; L'Esperance S; Bachvarova M; Plante M; Harel F; Bachvarov D
    Mod Pathol; 2008 Aug; 21(8):1002-10. PubMed ID: 18500265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
    Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
    Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
    BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
    Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
    Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
    Tsuda H; Birrer MJ; Ito YM; Ohashi Y; Lin M; Lee C; Wong WH; Rao PH; Lau CC; Berkowitz RS; Wong KK; Mok SC
    Cancer Genet Cytogenet; 2004 Dec; 155(2):97-107. PubMed ID: 15571795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis.
    Hu J; Khanna V; Jones MW; Surti U
    Gynecol Oncol; 2003 Jun; 89(3):369-75. PubMed ID: 12798697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
    Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
    BMC Cancer; 2009 Oct; 9():368. PubMed ID: 19835627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
    Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
    Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SOX2 expression and prognostic significance in ovarian carcinoma.
    Pham DL; Scheble V; Bareiss P; Fischer A; Beschorner C; Adam A; Bachmann C; Neubauer H; Boesmueller H; Kanz L; Wallwiener D; Fend F; Lengerke C; Perner S; Fehm T; Staebler A
    Int J Gynecol Pathol; 2013 Jul; 32(4):358-67. PubMed ID: 23722508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas.
    Tapper J; Bützow R; Wahlström T; Seppälä M; Knuutila S
    Br J Cancer; 1997; 75(12):1782-7. PubMed ID: 9192982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
    Zhong M; Li J; Ding YQ; Song LL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.